156 related articles for article (PubMed ID: 20581466)
1. mTORC1 signaling in Parkinson's disease and L-DOPA-induced dyskinesia: A sensitized matter.
Santini E; Valjent E; Fisone G
Cell Cycle; 2010 Jul; 9(14):2713-8. PubMed ID: 20581466
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia.
Santini E; Heiman M; Greengard P; Valjent E; Fisone G
Sci Signal; 2009 Jul; 2(80):ra36. PubMed ID: 19622833
[TBL] [Abstract][Full Text] [Related]
3. Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia.
Brugnoli A; Napolitano F; Usiello A; Morari M
Neurobiol Dis; 2016 Jan; 85():155-163. PubMed ID: 26522958
[TBL] [Abstract][Full Text] [Related]
4. Thwarting dyskinesia by targeting mTORC1.
Klann E
Sci Signal; 2009 Jul; 2(80):pe42. PubMed ID: 19622830
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms of l-DOPA-induced dyskinesia.
Fisone G; Bezard E
Int Rev Neurobiol; 2011; 98():95-122. PubMed ID: 21907084
[TBL] [Abstract][Full Text] [Related]
6. Dopamine- and cAMP-regulated phosphoprotein of 32-kDa (DARPP-32)-dependent activation of extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin complex 1 (mTORC1) signaling in experimental parkinsonism.
Santini E; Feyder M; Gangarossa G; Bateup HS; Greengard P; Fisone G
J Biol Chem; 2012 Aug; 287(33):27806-12. PubMed ID: 22753408
[TBL] [Abstract][Full Text] [Related]
7. mTOR inhibition alleviates L-DOPA-induced dyskinesia in parkinsonian rats.
Decressac M; Björklund A
J Parkinsons Dis; 2013; 3(1):13-7. PubMed ID: 23938307
[TBL] [Abstract][Full Text] [Related]
8. Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-/-) aphakia mice.
Solís O; Espadas I; Del-Bel EA; Moratalla R
Neurobiol Dis; 2015 Jan; 73():49-59. PubMed ID: 25281315
[TBL] [Abstract][Full Text] [Related]
9. Differential Activation States of Direct Pathway Striatal Output Neurons during l-DOPA-Induced Dyskinesia Development.
Figge DA; Oliveira HA; Crim J; Cowell RM; Standaert DG; Eskow Jaunarajs KL
J Neurosci; 2024 Jun; 44(26):. PubMed ID: 38664012
[TBL] [Abstract][Full Text] [Related]
10. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
Suárez LM; Solís O; Caramés JM; Taravini IR; Solís JM; Murer MG; Moratalla R
Biol Psychiatry; 2014 May; 75(9):711-22. PubMed ID: 23769604
[TBL] [Abstract][Full Text] [Related]
11. Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.
Fiorentini C; Savoia P; Savoldi D; Barbon A; Missale C
Neurobiol Dis; 2013 Jun; 54():339-48. PubMed ID: 23328768
[TBL] [Abstract][Full Text] [Related]
12. CK2 Oppositely Modulates l-DOPA-Induced Dyskinesia via Striatal Projection Neurons Expressing D1 or D2 Receptors.
Cortés M; Malave L; Castello J; Flajolet M; Cenci MA; Friedman E; Rebholz H
J Neurosci; 2017 Dec; 37(49):11930-11946. PubMed ID: 29097596
[TBL] [Abstract][Full Text] [Related]
13. Involvement of Autophagy in Levodopa-Induced Dyskinesia.
Feyder M; Plewnia C; Lieberman OJ; Spigolon G; Piccin A; Urbina L; Dehay B; Li Q; Nilsson P; Altun M; Santini E; Sulzer D; Bezard E; Borgkvist A; Fisone G
Mov Disord; 2021 May; 36(5):1137-1146. PubMed ID: 33460487
[TBL] [Abstract][Full Text] [Related]
14. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
Fox SH; Chuang R; Brotchie JM
Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047
[TBL] [Abstract][Full Text] [Related]
15. Striatal overexpression of β-arrestin2 counteracts L-dopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's disease rats.
Zhang ZR; Zhang XR; Luan XQ; Wang XS; Wang WW; Wang XY; Shao B; Xie CL
Neurochem Int; 2019 Dec; 131():104543. PubMed ID: 31491493
[TBL] [Abstract][Full Text] [Related]
16. Parkinson's disease: levodopa-induced dyskinesia and signal transduction.
Santini E; Valjent E; Fisone G
FEBS J; 2008 Apr; 275(7):1392-1399. PubMed ID: 18279379
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin, by Inhibiting mTORC1 Signaling, Prevents the Loss of Striatal Bidirectional Synaptic Plasticity in a Rat Model of L-DOPA-Induced Dyskinesia.
Calabrese V; Di Maio A; Marino G; Cardinale A; Natale G; De Rosa A; Campanelli F; Mancini M; Napolitano F; Avallone L; Calabresi P; Usiello A; Ghiglieri V; Picconi B
Front Aging Neurosci; 2020; 12():230. PubMed ID: 32848709
[TBL] [Abstract][Full Text] [Related]
18. Derangement of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and extracellular signal-regulated kinase (ERK) dependent striatal plasticity in L-DOPA-induced dyskinesia.
Cerovic M; Bagetta V; Pendolino V; Ghiglieri V; Fasano S; Morella I; Hardingham N; Heuer A; Papale A; Marchisella F; Giampà C; Calabresi P; Picconi B; Brambilla R
Biol Psychiatry; 2015 Jan; 77(2):106-15. PubMed ID: 24844602
[TBL] [Abstract][Full Text] [Related]
19. Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice.
Mango D; Bonito-Oliva A; Ledonne A; Cappellacci L; Petrelli R; Nisticò R; Berretta N; Fisone G; Mercuri NB
Exp Neurol; 2014 Nov; 261():733-43. PubMed ID: 25173217
[TBL] [Abstract][Full Text] [Related]
20. 5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction.
Fanni S; Scheggi S; Rossi F; Tronci E; Traccis F; Stancampiano R; De Montis MG; Devoto P; Gambarana C; Bortolato M; Frau R; Carta M
Neurobiol Dis; 2019 Jan; 121():120-130. PubMed ID: 30261284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
